Compare Global X MSCI Argentina ETF (ARGT) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X MSCI Argentina ETF vs Cassava Sciences Inc — how do they compare? Global X MSCI Argentina ETF trades at $92.45, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Global X MSCI Argentina ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ARGT | FLNA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $4.64 |
52-Week Low | $67.55 | $0.87 |
Market Cap | — | $47.75M |
Enterprise Value | — | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARGT trades at $92.96, up 0.43% with a bearish technical signal from moving averages. The ETF shows neutral oscillators with RSI at 44.95. Recent Seeking Alpha analysis (June 18, 2026) highlights a 28% upside potential as Argentina's economic reforms progress, with the fund trading at 12.5x earnings below its post-Milei average.
The outlook suggests potential re-rating to 14-18x earnings could yield 12-44% upside, supported by Argentina's improving monetary backdrop. Key risks include country-specific volatility and concentrated holdings in MercadoLibre. Institutional interest is growing with Stanley Druckenmiller's recent position accumulation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
